共 262 条
[1]
Reyes DK(2015)The biology and treatment of oligometastatic cancer Oncotarget 6 8491-8524
[2]
Pienta KJ(2020)Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation Lancet Oncol 21 e18-e28
[3]
Guckenberger M(2016)Stereotactic body radiotherapy in the management of oligometastatic disease Cancer Control 23 21-29
[4]
Lievens Y(2020)Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document Radiother Oncol 148 157-166
[5]
Bouma AB(2020)Radiation in the treatment of oligometastatic and oligoprogressive disease: rationale, recent data, and research questions Cancer J 26 156-165
[6]
Collette L(2019)Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: some patients survive longer than a decade Radiother Oncol 131 45-51
[7]
Dekker A(2011)Phase II study of helical tomotherapy for oligometastatic colorectal cancer Ann Oncol 22 362-368
[8]
deSouza NM(2019)Predictive factors for response and survival in a cohort of oligometastatic patients treated with stereotactic body radiation therapy Int J Radiat Oncol Biol Phys 104 111-121
[9]
Dingemans AC(2019)Hypofractionated stereotactic radiotherapy for non-breast or prostate cancer oligometastases: a tail of survival beyond 10 years Front Oncol 9 111-e320
[10]
Fournier B(2020)A Large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 Study): a collaboration of MITO, AIRO GYN, and MaNGO Groups Oncologist 25 e311-262